Educational research content only. Not medical advice, diagnosis, or treatment. Nothing on this site is intended to promote human use, self-administration, or the substitution of professional healthcare.

NovaGenesis Peptide Research
← Peptide Library
COGNITIVE RESEARCHSMX

Semax

A synthetic ACTH-derived peptide studied for cognitive signalling, neurotrophic factor interaction, and attention research.

Half-Life
Short
Onset
Fast
Symbol
SMX
Category
Cognitive

⏱ Half-Life

Short duration profile

Semax demonstrates a short half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Fast measurable response

Onset is observed as fast — a property that influences how researchers structure comparative studies versus other compounds in the cognitive research category.

🧠 Key Notes

What makes it distinct

  • 01Often studied alongside Selank
  • 02Short systemic half-life with rapid measurable effect
  • 03Investigated via intranasal research delivery

🧬 Mechanism of Action

How it works

Semax is a synthetic heptapeptide modelled on the ACTH(4–10) fragment, with a stabilising C-terminal Pro-Gly-Pro tail that resists enzymatic degradation. It acts centrally to upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), enhancing neuronal plasticity, dendritic growth, and synaptic resilience. It also modulates dopaminergic and serotonergic signalling and supports the body's endogenous opioid balance. Despite a short plasma half-life, downstream central effects persist for hours, indicating durable transcriptional changes rather than direct receptor occupancy.

✨ Documented Benefits

What the research shows it supports

B01Enhances attention, memory consolidation, and learning in research models.
B02Increases BDNF and NGF expression — neurotrophic factors central to cognitive plasticity.
B03Provides neuroprotective effects in models of stroke, hypoxia, and oxidative stress.
B04Improves stress resilience and supports balanced HPA-axis activity.
B05Effective via intranasal administration, allowing direct nose-to-brain delivery.

🔍 Research Insights

What the literature shows

INSIGHT 01

Increases BDNF and NGF expression in central tissue research — neurotrophic factors tied to plasticity and learning.

INSIGHT 02

Despite a short plasma half-life, central effects persist for hours, suggesting durable downstream signalling.

INSIGHT 03

Originally developed in Russian neuroscience research as a stable analog of ACTH(4–10).

🧪 Typical Research Use Cases

Where it appears in study design

USE CASE 01

Attention, memory, and learning research models.

USE CASE 02

Stress-response and neuroprotection studies.

USE CASE 03

Intranasal pharmacokinetic and bioavailability work.

🔬 Study Deep Dive

Semax, an Analogue of Adrenocorticotropin (4–10), Prevents Learning Deficits Caused by Prenatal Hypoxia

Manchenko DM, et al. · Neuroscience · 2002

Design

Controlled preclinical behavioural study in rat model of prenatal hypoxia.

Population

Wistar rat pups exposed to prenatal hypoxia.

Intervention

Intranasal Semax (50 μg/kg) during postnatal development window.

Primary Finding

Reversed hypoxia-induced deficits in learning and memory tasks, restoring performance close to non-hypoxic controls.

TAKEAWAY

Early evidence for Semax's neuroprotective and cognitive-restorative signalling — the basis for its later use in neurology research protocols.

Read the full study ↗

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

  1. [01]

    Dolotov, O. V. et al. (2006). Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82–86.

    Journal of Neurochemistry ↗
  2. [02]

    Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat'ko, V. N., Zhuravleva, E. I., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii, 97(6), 26–34.

    Zh Nevrol Psikhiatr ↗
  3. [03]

    Shadrina, M. I. et al. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35.

    Journal of Molecular Neuroscience ↗
  4. [04]

    Medvedeva, E. V. et al. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics, 15, 228.

    BMC Genomics ↗

⚠️ Not Medical Advice

Educational research summary only

This profile summarises published research on Semax. It is not medical advice, diagnosis, or treatment, and it is not intended to promote human use, self-administration, or the substitution of professional healthcare. Discuss any health decision with a licensed clinician.

Continue Exploring

Also explore: Selank, PT-141, MOTS-c, Dihexa, Epitalon

Selank →PT-141 →MOTS-c →Dihexa →Epitalon →Half-Life Guide →Cognitive Research →